

			TMENT OF COMMERCE Attome) ID TRADEMARK OFFICE Serial N		ocket No. 06132/065003 10/789,842		
INFORMATION DISCLOSURE				Applicant		Monath et al.	
STATEMENT BY APPLICANT (Use several sheets if necessary)			Filing Date		February	February 27, 2004	
	(O36 36 VEI BI	Silects ii licecs.	oury)	Group		1648	
(37 C.F.R. § 1	.98(b))			IDS Filed		February	16 , 2005
			U.S. PATENT DOCUMEN	тѕ			
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant Class		Subclass	Filing Date (If Appropriate)	
	FOREI	GN PATENTS (OR PUBLISHED FOREIGN	PATENT AF	PLICATIO	NS	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)
	OTHER DOCL	MENTS (INCL	UDING AUTHOR, TITLE, D	ATE, PLAC	OF PUBL	ICATION)	
SBC	Chen et al., "Gene and in Vitro," Viro		aracterization of Organ-Trop 1996.	oism Mutants	of Japane	se Encephal	itis Virus <i>in Vivo</i>
SBC	Guirakhoo et al., "A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys," J. Virology 78(18):9998-10008, 2004.						
SBC			ue Virus Major Envelope Pr he Protein," Virology 232:28			Their Local	ization on the
	•						
EXAMINER	/Stacy B.	Chen/ (07	7/17/2006) DATE CO	NSIDERED	07/17/	2006	
EXAMINER: In form with the n	itial citation conside ext communication	red. Draw line to applicant.	through citation if not in cor	nformance a	nd not cons	sidered. Incl	ude copy of this

1

Sheet 1 of 3 06132/065003 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PTO-1449 PATENT AND TRADEMARK OFFICE (MODIFIED) Serial No. 10/789,842 **Applicant** Thomas P. Monath et al. INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT (Use several sheets if necessary) 1648 Group (37 C.F.R. § 1.98(b)) IDS Filed July 26, 2004 **U.S. PATENTS** Patent Number Issue Date Class Subclass Filing Date **Examiner's** Patentee or Applicant Οſ (If Appropriate) Initials Patent **Publication Publication** Date Number SBC 6,171,854 B1 01/09/01 Galler et al. 6,184,024 B1 02/06/01 Lai et al. 6,696,281 02/24/04 Chambers et al. 03/0194801 10/16/03 Bonaldo et al. FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Subclass Translation Examiner's Document **Publication** Country or Class Date Patent Office (Yes/No) Initials Number WO 93/06214 04/01/93 WIPO WO 98/37911 09/03/98 **WIPO WIPO** WO 01/39802 07/06/01 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Arroyo et al., "Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development," Trends in Molecular Medicine 7:350-354, 2001. Arroyo et al., "Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)," Journal of Virology 75:934-942, 2001. Bray et al., "Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes," Proc. Natl. Acad. U.S.A. 88:10342-10346, 1991. Bray et al., "Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence," Journal of Virology 72:1647-1651, 1998. Caufour et al., "Construction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Viruses," Virus Research 1-14, 2001. Chambers et al., "Mutagenesis of the Yellow Fever Virus NS2B/3 Cleavage Site: Determinants of Cleavage Site Specificity and Effects on Polyprotein Processing and Viral Replication," J. Virol. 1600-1605, 1995. /Stacy B. Chen/ (07/17/2006) DATE CONSIDERED 07/17/2006 **EXAMINER** EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this

- 40 m

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06132/065003	
(MODIFIED)		Serial No.	10/789,842	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Thomas P. Monath et al.	
		Filing Date	February 27, 2004	
		Group	1648	
(37 C.F.R. § 1.98(b))		IDS Filed	July 26, 2004	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

SBC	Chambers et al., "Vaccine Development Against Dengue and Japanese Encephalitis: Report of a World Health Organization Meeting," Vaccine 15:1494-1502, 1997.			
•	Chambers et al., "Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties Journal of Virology 73:3095-3101, 1999.			
	Cola et al., "Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order and Characteristics of the Virus-Specified Proteins," J. Gen. Virol. 69:1-21, 1988.			
•	dos Santos et al., "Determinants in the Envelope E Protein and Viral RNA Helicase NS3 that Influence the Induction of Apoptosis in Response to Infection with Dengue Type 1 Virus," Virology 274:292-308, 2000.			
	Duarte dos Santos et al., "Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213," Virus Research 35:35-41, 1995.			
	Galler et al., "The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and its Use as an Expression Vector," Braz. J. Biol. Res. 30:157-168, 1997.			
	Galler et al., "Genetic Variability Among Yellow Fever Virus 17D Substrains," Vaccine 16:1-5, 1998.			
	Guirakhoo et al., "Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever- Dengue Virus Tetravalent Vaccine," Journal of Virology 75:7290-7304, 2001.			
•	Hurrelbrink and McMinn, "Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein," Journal of Virology 75:7692-7702, 2001			
·	Kanesa-thasan et al., "Safety and Immunogenicity of Attenuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers," Vaccine 19:3179-3188, 2001.			
	Lai et al., "Evaluation of Molecular Strategies to Develop a Live Dengue Vaccine," Clin. Diag. Virol. 10:173-179, 1998.			
	Mandl et al., "Sequence of the Genes Encoding the Structural Proteins of the Low-Virulence Tick-Borne Flaviviruses Langat TP21 and Yelantsev," Virol. 185:891-895, 1991.			
	Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic-Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," Virol. 194:173-184, 1993.			
	Marchevsky et al., "Phenotypic Analysis of Yellow Fever Virus Derived from Complementary DNA," American J. Tropical Medicine & Hygiene 52:75-80, 1995.			
Ψ	McMinn, "The Molecular Basis of Virulence of the Encephalitogenic Flaviviruses," Journal of General Virology 78:2711-2722, 1997.			
XAMINER	/Stacy B. Chen/ (07/17/2006) DATE CONSIDERED 07/17/2006			

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06132/065003
(MODIFIED)		Serial No.	10/789,842
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Thomas P. Monath et al.
		Filing Date	February 27, 2004
		Group	1648
(37 C.F.R. § 1.98(b))		IDS Filed	July 26, 2004

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

sBC	Monath et al., "Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines," Journal of Virology 76:1932-1943, 2002.			
•	Monath, "Molecular Distinctions Between Attenuated (Vaccine) and Virulent Yellow Fever Viruses," In, Plotkin SA and Orenstein WA (eds). Vaccines, 3 rd edition, Saunders (Philadelphia), pp. 815-879, 1999.			
	Pletnev et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," Proc. Natl. Acad. Sci. U.S.A. 89:10532-10536, 1992.			
•	Rey et al., "The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2Å Resolution," Nature 375:29 298, 1995.			
	Rice et al., "Transcription of Infectious Yellow Fever RNA from Full-Length cDNA Templates Produced by In Vitro Ligation," The New Biologist 1:285-296, 1989.			
	Shiu et al., "Genomic Sequence of the Structural Proteins of Louping III Virus: Comparative Analysis with Tick-Borne Encephalitis Virus," Virology 180:411-415, 1991.			
	Stocks et al., "Signal Peptidase Cleavage at the Flavivirus C-prM Junction: Dependence on the Viral NS2B-3 Protease for Efficient Processing Requires Determinants in C, the Signal Peptide, and prM," J. Virol. 72:2141-2149, 1998.			
	Venugopal et al., "Towards a New Generation of Flavivirus Vaccines," Vaccines 12:966-975, 1994.			
	Wang et al., "Comparison of the Genomes of the Wild-Type French Viscerotropic Strain of Yellow Fever Virus with its Vaccine Derivative French Neurotropic Vaccine," Journal of General Virology 76:2749-2755, 1995.			
;	Chambers et al., U.S. Patent Application Serial No. 09/121,587, filed July 23, 1998.			
<u> </u>	Chambers et al., U.S. Patent Application Serial No. 10/701,122, filed November 4, 2003.			
EVALUNES	/Stacy B. Chen/ (07/17/2006) DATE CONSIDERED 07/17/2006			
EXAMINER	/Stacy B. Chen/ (07/17/2006) DATE CONSIDERED 07/17/2006			

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.